Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial
暂无分享,去创建一个
D. Kofler | J. Rech | S. Finzel | H. Schulze-Koops | W. Schmidt | H. Tony | S. Weiner | Christine App | R. Bergner | M. Mendelson | J. Thiel | C. Sieder | L. Unger | E. Pournara | M. Maricos | I. Andreica | P. Lamprecht | N. Venhoff
[1] A. Tomelleri,et al. Giant cell arteritis: Update on clinical manifestations, diagnosis, and management. , 2022, European journal of internal medicine.
[2] I. Wicks,et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2022, Annals of the Rheumatic Diseases.
[3] E. Matteson,et al. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study , 2022, Annals of the Rheumatic Diseases.
[4] W. Schmidt,et al. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial , 2021, Trials.
[5] G. Guyatt,et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis , 2021, Arthritis & rheumatology.
[6] J. Springer,et al. Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica. , 2021, The Medical clinics of North America.
[7] J. Pope,et al. A meta-analysis of the epidemiology of giant cell arteritis across time and space , 2020, Arthritis Research & Therapy.
[8] P. Geusens,et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study , 2019, ACR open rheumatology.
[9] A. Deodhar,et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study , 2019, RMD Open.
[10] C. Turesson,et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis , 2019, Annals of the rheumatic diseases.
[11] B. Griffiths,et al. Giant cell arteritis: new concepts, treatments and the unmet need that remains. , 2018, Rheumatology.
[12] M. Tomšič,et al. Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis. , 2018, Rheumatology.
[13] L. Sammut,et al. 002 Biopsy proven giant cell arteritis in a patient with psoriatic arthritis on TNF-alpha inhibitor treated with high dose prednisolone and a switch to secukinumab (anti IL-17) , 2018 .
[14] M. Cid,et al. Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved , 2018, Rheumatology.
[15] E. Matteson,et al. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities , 2017, Nature Reviews Rheumatology.
[16] B. Bonnotte,et al. Recent advances in our understanding of giant cell arteritis pathogenesis. , 2017, Autoimmunity reviews.
[17] J. Stone,et al. Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.
[18] J. Stone,et al. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy , 2016, Annals of the rheumatic diseases.
[19] S. Reichenbach,et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.
[20] M. Dougados,et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. , 2015, The New England journal of medicine.
[21] P. Merkel,et al. Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study , 2015, The Journal of Rheumatology.
[22] H. Petri,et al. Incidence of Giant Cell Arteritis and Characteristics of Patients: Data‐Driven Analysis of Comorbidities , 2015, Arthritis care & research.
[23] A. Gottlieb,et al. Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) , 2015, The British journal of dermatology.
[24] Roland Fisch,et al. Bayesian Design of Proof-of-Concept Trials , 2015, Therapeutic innovation & regulatory science.
[25] Mahboob Rahman,et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis , 2012, Annals of the rheumatic diseases.
[26] B. Bonnotte,et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. , 2012, Arthritis and rheumatism.
[27] R. Olshen,et al. Th17 and Th1 T-Cell Responses in Giant Cell Arteritis , 2010, Circulation.
[28] S. Gabriel,et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.
[29] R. Tomsak. Giant cell arteritis. , 2002, Ophthalmology.